Trials / Completed
CompletedNCT04823208
A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM)
A Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 64 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 20 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to learn about the side effects of LY3437943 when given to Japanese participants with type 2 diabetes mellitus. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Each enrolled participant will receive injections of LY3437943 or placebo given just under the skin. For each participant, the study will last up to 5 months, inclusive of screening and will include 16 visits to the study center.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3437943 | Administered SC |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2021-05-24
- Primary completion
- 2022-06-23
- Completion
- 2022-06-23
- First posted
- 2021-03-30
- Last updated
- 2022-08-22
Locations
4 sites across 1 country: Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04823208. Inclusion in this directory is not an endorsement.